Document is current
Any future updates will be listed below
-
Authors
van Beurden-Tan, Chrissy H. Y. https://orcid.org/0000-0002-0145-9855
Sonneveld, Pieter
Groot, Carin A. Uyl-de
-
Funding
Funding for this research was provided by:
ZonMw (152001020)
- License Information
-
More Information
Article History
Received: 18 April 2021
Accepted: 19 April 2022
First Online: 30 May 2022
Declarations
:
: Not applicable.Consent for publication.Not applicable.
: <b>Dr. Uyl-de Groot</b> reports grants from Boehringer Ingelheim, Astellas, Celgene, Sanofi, Janssen-Cilag, Bayer, Amgen, Gemzyme, Merck, Gilead, Novartis, Glycostem Therapeutics, Astra Zeneca, and Roche, outside the submitted work. <b>Dr. Sonneveld</b> reports research support from Amgen, Celgene, Janssen, Karyopharm, and SkylineDx, reports participation in advisory boards of Amgen, Celgene, Genentech, Janssen, Karyopharm, and SkylineDx, outside the submitted work. <b>Van Beurden-Tan</b> is full-time employed as contract worker at Amgen since November 1st, 2018, reports no grants and research funding, no consultancies, no travel grants, no speaking fees, no writing fees and other honoraria, outside the submitted work.
